JP2018506983A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506983A5 JP2018506983A5 JP2017545941A JP2017545941A JP2018506983A5 JP 2018506983 A5 JP2018506983 A5 JP 2018506983A5 JP 2017545941 A JP2017545941 A JP 2017545941A JP 2017545941 A JP2017545941 A JP 2017545941A JP 2018506983 A5 JP2018506983 A5 JP 2018506983A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- retroviral
- vector
- mitogenic
- lentiviral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 45
- 230000001177 retroviral effect Effects 0.000 claims description 37
- 108091005703 transmembrane proteins Proteins 0.000 claims description 34
- 102000035160 transmembrane proteins Human genes 0.000 claims description 34
- 230000002297 mitogenic effect Effects 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 24
- 239000013603 viral vector Substances 0.000 claims description 22
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 20
- 230000006044 T cell activation Effects 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 238000004806 packaging method and process Methods 0.000 claims description 11
- 229960002685 biotin Drugs 0.000 claims description 10
- 235000020958 biotin Nutrition 0.000 claims description 10
- 239000011616 biotin Substances 0.000 claims description 10
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 9
- 108010090804 Streptavidin Proteins 0.000 claims description 8
- 108700004030 rev Genes Proteins 0.000 claims description 6
- 241001430294 unidentified retrovirus Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 101150098213 rev gene Proteins 0.000 claims description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 4
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100021696 Syncytin-1 Human genes 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 210000004779 membrane envelope Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 241001504519 Papio ursinus Species 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108700004026 gag Genes Proteins 0.000 claims 1
- 108700004029 pol Genes Proteins 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201503500A GB201503500D0 (en) | 2015-03-02 | 2015-03-02 | Cell |
| GB1503500.9 | 2015-03-02 | ||
| PCT/GB2016/050537 WO2016139463A1 (en) | 2015-03-02 | 2016-03-01 | Retroviral and lentiviral vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020050861A Division JP2020092722A (ja) | 2015-03-02 | 2020-03-23 | レトロウイルスおよびレンチウイルスベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506983A JP2018506983A (ja) | 2018-03-15 |
| JP2018506983A5 true JP2018506983A5 (enExample) | 2019-01-24 |
| JP6695347B2 JP6695347B2 (ja) | 2020-05-20 |
Family
ID=52876362
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545941A Active JP6695347B2 (ja) | 2015-03-02 | 2016-03-01 | レトロウイルスおよびレンチウイルスベクター |
| JP2020050861A Withdrawn JP2020092722A (ja) | 2015-03-02 | 2020-03-23 | レトロウイルスおよびレンチウイルスベクター |
| JP2023029559A Withdrawn JP2023060000A (ja) | 2015-03-02 | 2023-02-28 | レトロウイルスおよびレンチウイルスベクター |
| JP2025227149A Pending JP2026026312A (ja) | 2015-03-02 | 2025-12-03 | レトロウイルスおよびレンチウイルスベクター |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020050861A Withdrawn JP2020092722A (ja) | 2015-03-02 | 2020-03-23 | レトロウイルスおよびレンチウイルスベクター |
| JP2023029559A Withdrawn JP2023060000A (ja) | 2015-03-02 | 2023-02-28 | レトロウイルスおよびレンチウイルスベクター |
| JP2025227149A Pending JP2026026312A (ja) | 2015-03-02 | 2025-12-03 | レトロウイルスおよびレンチウイルスベクター |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10954530B2 (enExample) |
| EP (2) | EP3265570B2 (enExample) |
| JP (4) | JP6695347B2 (enExample) |
| KR (1) | KR20180002602A (enExample) |
| CN (1) | CN107406860A (enExample) |
| AU (1) | AU2016227474A1 (enExample) |
| BR (1) | BR112017018251A2 (enExample) |
| CA (1) | CA2977472A1 (enExample) |
| CL (1) | CL2017002199A1 (enExample) |
| ES (1) | ES2877398T5 (enExample) |
| GB (1) | GB201503500D0 (enExample) |
| IL (1) | IL253820B (enExample) |
| MX (1) | MX2017010553A (enExample) |
| RU (1) | RU2017133854A (enExample) |
| SG (1) | SG11201706721PA (enExample) |
| WO (1) | WO2016139463A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201602887QA (en) | 2013-10-25 | 2016-05-30 | Psioxus Therapeutics Ltd | Oncolytic adenoviruses armed with heterologous genes |
| GB201415344D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
| KR101697473B1 (ko) | 2014-11-26 | 2017-01-18 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
| SG11201708604TA (en) | 2015-04-30 | 2017-11-29 | Psioxus Therapeutics Ltd | Oncolytic adenovirus encoding a b7 protein |
| US10046317B2 (en) * | 2015-08-11 | 2018-08-14 | Chevron U.S.A. Inc. | Middle distillate hydrocracking catalyst containing zeolite beta with low OD acidity and large domain size |
| HK1258932A1 (zh) | 2015-10-22 | 2019-11-22 | Juno Therapeutics Gmbh | 用於转导的方法、反应剂盒、反应剂和设备 |
| EA201891022A1 (ru) * | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| CN108884460B (zh) * | 2016-03-19 | 2023-04-28 | 埃克苏马生物技术公司 | 淋巴细胞转导及其扩增调节的方法与组合物 |
| GB201614093D0 (en) * | 2016-08-17 | 2016-09-28 | Autolus Ltd | Vector |
| MY197324A (en) | 2016-08-29 | 2023-06-13 | Akamis Bio Ltd | Adenovirus armed with bispecific t cell activator |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| MA46998A (fr) * | 2016-12-05 | 2019-10-09 | Juno Therapeutics Inc | Production de cellules modifiées pour une thérapie cellulaire adoptive |
| US11535666B2 (en) * | 2016-12-30 | 2022-12-27 | Cytocares (Shanghai) Inc. | Trifunctional molecule and application thereof |
| WO2018120842A1 (zh) * | 2016-12-30 | 2018-07-05 | 上海欣百诺生物科技有限公司 | 一种双功能分子及其应用 |
| KR102879522B1 (ko) * | 2017-03-03 | 2025-11-04 | 엑수마 바이오테크, 코포레이션 | 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물 |
| EP3633029A4 (en) * | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| CN111479921B (zh) * | 2017-09-18 | 2024-08-02 | 埃克苏马生物技术公司 | 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物 |
| ES2956241T3 (es) * | 2017-12-20 | 2023-12-15 | Miltenyi Biotec Bv & Co Kg | Método para la transducción de células NK |
| CN112262214A (zh) | 2018-04-12 | 2021-01-22 | 优莫佳生物制药股份有限公司 | 病毒载体及包装细胞系 |
| EP4455166A3 (en) * | 2018-08-10 | 2025-01-15 | Kyoto University | Method for producing cd3-positive cell |
| CA3111084A1 (en) * | 2018-09-02 | 2020-03-05 | Exuma Biotech, Corp | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| MY199770A (en) | 2018-11-14 | 2023-11-22 | Green Cross Lab Cell Corp | Method for culturing cord blood-derived natural killer cells using transformed t cells |
| WO2020106992A1 (en) | 2018-11-21 | 2020-05-28 | Umoja Biopharma, Inc. | Multicistronic vector for surface engineering lentiviral particles |
| CN109722420A (zh) * | 2019-03-15 | 2019-05-07 | 江苏艾洛特医药研究院有限公司 | 一种改良嵌合抗原受体t细胞的制备及其应用 |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| CA3154281A1 (en) | 2019-10-16 | 2021-04-22 | Andrew Scharenberg | Retroviral vector for universal receptor therapy |
| CN115697388A (zh) | 2020-01-30 | 2023-02-03 | 优莫佳生物制药股份有限公司 | 双特异性转导增强子 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| JP2023551220A (ja) | 2020-11-20 | 2023-12-07 | ウモジャ バイオファーマ インコーポレイテッド | 複数のポリヌクレオチドを送達するためのベクター系およびその使用法 |
| MX2023008831A (es) | 2021-01-27 | 2023-10-19 | Umoja Biopharma Inc | Lentivirus para generar células que expresan receptores de antígeno quimérico anti-cd19. |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023143209A1 (zh) * | 2022-01-25 | 2023-08-03 | 广东东阳光药业股份有限公司 | 病毒载体及其应用 |
| CN119365208A (zh) | 2022-04-13 | 2025-01-24 | 巴塞罗那自治大学 | 通过表达klotho蛋白的基因疗法治疗神经肌肉疾病 |
| KR20250011945A (ko) | 2022-05-17 | 2025-01-22 | 우모자 바이오파마 인코포레이티드 | 바이러스 입자의 제조 |
| AU2023371650A1 (en) | 2022-11-04 | 2025-05-29 | Umoja Biopharma, Inc. | Polynucleotide construct and related viral vectors and methods |
| KR20250121163A (ko) | 2022-11-04 | 2025-08-11 | 우모자 바이오파마 인코포레이티드 | 융합 분자를 디스플레이하는 렌티바이러스 입자 및 이의 용도 |
| WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN120769904A (zh) * | 2023-02-27 | 2025-10-10 | 上海君赛生物科技有限公司 | 表达膜结合细胞因子的肿瘤浸润淋巴细胞 |
| KR20260005358A (ko) * | 2023-04-27 | 2026-01-09 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 항-cd3 디스플레이를 갖는 슈도타이핑된 레트로바이러스 벡터 입자 |
| WO2024238153A1 (en) | 2023-05-15 | 2024-11-21 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd20 chimeric antigen receptors |
| CN116496417B (zh) * | 2023-06-27 | 2023-10-10 | 北京市肿瘤防治研究所 | 含有膜型il7的融合蛋白及t细胞 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025072257A1 (en) * | 2023-09-25 | 2025-04-03 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| IL327308A (en) | 2023-09-25 | 2026-05-01 | Kelonia Therapeutics Inc | Antigen-binding polypeptides |
| AU2024353718A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| WO2025090978A1 (en) | 2023-10-26 | 2025-05-01 | Cargo Therapeutics, Inc. | Modified immune effector cells |
| WO2025149068A1 (zh) * | 2024-01-10 | 2025-07-17 | 深圳市济因生物科技有限公司 | 一种病毒颗粒及其制备方法与应用 |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
| WO2026052028A1 (zh) * | 2024-09-05 | 2026-03-12 | 深圳市济因生物科技有限公司 | 一种制备表达car的t细胞的方法及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7097494A (en) * | 1993-06-01 | 1994-12-20 | Targeted Genetics Corporation | Envelope fusion vectors for use in gene delivery |
| WO1997005266A1 (en) | 1995-07-25 | 1997-02-13 | Introgene B.V. | Methods and means for targeted gene delivery |
| WO2004080404A2 (en) | 2003-03-07 | 2004-09-23 | University Of Utah Research Foundation | Il-2 transmembrane constructs |
| EP1769078A1 (en) * | 2004-07-01 | 2007-04-04 | VIRxSYS Corporation | Vector packaging cell line |
| RU2007126553A (ru) * | 2004-12-13 | 2009-01-20 | Цитос Биотехнологи Аг (Ch) | Упорядоченные ряды антигенов ил-15 и их применение |
| WO2007095201A2 (en) | 2006-02-15 | 2007-08-23 | The Regents Of The University Of California | Pseudotyped retroviral vectors and methods of use thereof |
| WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| GB0920775D0 (en) * | 2009-11-26 | 2010-01-13 | King S College | Cells |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| GB201415344D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
| GB201614093D0 (en) | 2016-08-17 | 2016-09-28 | Autolus Ltd | Vector |
| GB201910651D0 (en) | 2019-07-25 | 2019-09-11 | Autolus Ltd | Virus-like particle |
-
2015
- 2015-03-02 GB GB201503500A patent/GB201503500D0/en not_active Ceased
-
2016
- 2016-03-01 EP EP16709502.5A patent/EP3265570B2/en active Active
- 2016-03-01 WO PCT/GB2016/050537 patent/WO2016139463A1/en not_active Ceased
- 2016-03-01 US US15/554,499 patent/US10954530B2/en active Active
- 2016-03-01 AU AU2016227474A patent/AU2016227474A1/en not_active Abandoned
- 2016-03-01 SG SG11201706721PA patent/SG11201706721PA/en unknown
- 2016-03-01 CN CN201680013282.6A patent/CN107406860A/zh active Pending
- 2016-03-01 MX MX2017010553A patent/MX2017010553A/es unknown
- 2016-03-01 ES ES16709502T patent/ES2877398T5/es active Active
- 2016-03-01 RU RU2017133854A patent/RU2017133854A/ru not_active Application Discontinuation
- 2016-03-01 EP EP21171660.0A patent/EP3904523A1/en active Pending
- 2016-03-01 CA CA2977472A patent/CA2977472A1/en not_active Abandoned
- 2016-03-01 KR KR1020177027017A patent/KR20180002602A/ko not_active Abandoned
- 2016-03-01 BR BR112017018251-3A patent/BR112017018251A2/pt not_active Application Discontinuation
- 2016-03-01 JP JP2017545941A patent/JP6695347B2/ja active Active
-
2017
- 2017-08-03 IL IL253820A patent/IL253820B/en active IP Right Grant
- 2017-08-30 CL CL2017002199A patent/CL2017002199A1/es unknown
-
2020
- 2020-03-23 JP JP2020050861A patent/JP2020092722A/ja not_active Withdrawn
-
2021
- 2021-03-04 US US17/192,561 patent/US11814641B2/en active Active
-
2023
- 2023-02-28 JP JP2023029559A patent/JP2023060000A/ja not_active Withdrawn
-
2024
- 2024-12-19 US US18/987,004 patent/US20250388929A1/en active Pending
-
2025
- 2025-12-03 JP JP2025227149A patent/JP2026026312A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017133854A (ru) | Вектор | |
| Kolchinsky et al. | Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops | |
| Mebatsion et al. | A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells | |
| Yang et al. | Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins | |
| Morizono et al. | Antibody-directed targeting of retroviral vectors via cell surface antigens | |
| JP2019509063A5 (enExample) | ||
| JP7105875B2 (ja) | レトロウイルスベクター | |
| EP2583974A1 (en) | Pseudotyping of foamy viruses | |
| Shimizu et al. | An orphan G protein-coupled receptor, GPR1, acts as a coreceptor to allow replication of human immunodeficiency virus types 1 and 2 in brain-derived cells | |
| Kayman et al. | The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system | |
| US20240124848A1 (en) | Stable lentivirus packaging cell line and preparation method therefor | |
| Yang et al. | Role of the gp120 inner domain β-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits | |
| Swanstrom et al. | Sequencing the biology of entry: the retroviral env gene | |
| Uhlig et al. | Lentiviral protein transfer vectors are an efficient vaccine platform and induce a strong antigen-specific cytotoxic T cell response | |
| US20240401077A1 (en) | Koala retrovirus envelope gylcoproteins and uses thereof | |
| US20240190988A1 (en) | Novel chimeric antigen receptors and libraries | |
| Vahlenkamp et al. | A single amino acid substitution in the transmembrane envelope glycoprotein of feline immunodeficiency virus alters cellular tropism | |
| Buffa et al. | A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1) HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice | |
| Steidl et al. | Coreceptor Switch of [MLV (SIVagm)] pseudotype vectors by V3-loop exchange | |
| JP2014528729A (ja) | ウイルスベクター精製システム | |
| Tsukahara et al. | Characterization of envelope glycoprotein mutants for human T-cell leukemia virus type 1 infectivity and immortalization | |
| WO2024220597A2 (en) | Digital droplet based assay for detecting replication competent lentiviral vector | |
| Jeun et al. | Discovery of a novel envelope protein derived from simian retrovirus 2 for pseudotyping retroviral vectors used for production of CAR immune cells | |
| EP1739180A1 (en) | T cell line-based packaging cell line for the production of retroviruses by enriching of CD3 expressing cells | |
| Sparacio et al. | Inter-retroviral fusion mediated by human immunodeficiency virus or murine leukemia virus glycoproteins: independence of cellular membranes and membrane vesicles |